Literature DB >> 36229904

Statin Intake and Gastric Cancer Risk: An Updated Subgroup Meta-analysis Considering Immortal Time Bias.

Jong-Myon Bae1.   

Abstract

A retrospective record-linkage study (RLS) based on medical records containing drug prescription histories involves immortal time bias (ITB). Thus, it is necessary to control for this bias in the research planning and analysis stages. Furthermore, a summary of a metaanalysis including RLSs that did not control for ITB showed that specific drugs had a preventive effect on the occurrence of the disease. Previous meta-analytic results of three systematic reviews evaluating the association between statin intake and gastric cancer risk showed that the summary hazard ratio (sHR) of the RLSs was lower than 1 and was statistically significant. We should consider the possibility of ITB in the sHR of RLSs and interpret the results carefully.

Entities:  

Keywords:  Bias; Data linkage; Hydroxymethylglutaryl-CoA reductase inhibitors; Meta-analysis; Stomach neoplasms

Mesh：

Substances：

Year:  2022        PMID： 36229904      PMCID： PMC9561136          DOI： 10.3961/jpmph.22.209

Source DB:  PubMed          Journal:  J Prev Med Public Health        ISSN： 1975-8375


  24 in total

1.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

Review 2.  Immortal time bias in pharmaco-epidemiology.

Authors:  Samy Suissa
Journal:  Am J Epidemiol       Date:  2007-12-03       Impact factor: 4.897

3.  Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan.

Authors:  Yasuyuki Matsushita; Masahiro Sugihara; Junpei Kaburagi; Masumi Ozawa; Mikio Iwashita; Sanae Yoshida; Hanako Saito; Yoko Hattori
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-02       Impact factor: 2.890

4.  Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients.

Authors:  Gary D Friedman; E Dawn Flick; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-01       Impact factor: 2.890

5.  Meta-epidemiology.

Authors:  Jong-Myon Bae
Journal:  Epidemiol Health       Date:  2014-09-25

6.  Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study.

Authors:  Shinichi Sato; Wakiko Ajiki; Tohru Kobayashi; Nobuhisa Awata
Journal:  J Epidemiol       Date:  2006-09       Impact factor: 3.211

7.  Association of Aspirin, Metformin, and Statin Use with Gastric Cancer Incidence and Mortality: A Nationwide Cohort Study.

Authors:  Mi Hee Cho; Tae Gon Yoo; Su-Min Jeong; Dong Wook Shin
Journal:  Cancer Prev Res (Phila)       Date:  2020-09-16

8.  Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.

Authors:  Jonathan R Emberson; Patricia M Kearney; Lisa Blackwell; Connie Newman; Christina Reith; Neeraj Bhala; Lisa Holland; Richard Peto; Anthony Keech; Rory Collins; John Simes; Colin Baigent
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

Review 9.  Gastric Cancer: How Can We Reduce the Incidence of this Disease?

Authors:  Caroline M den Hoed; Ernst J Kuipers
Journal:  Curr Gastroenterol Rep       Date:  2016-07

10.  Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling.

Authors:  Qing Liu; Hongwei Xia; Sheng Zhou; Qiulin Tang; Jitao Zhou; Min Ren; Feng Bi
Journal:  Onco Targets Ther       Date:  2020-03-09       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.